Spectrum Pharmaceuticals' stock drops after the company receives a dreaded CRL from the FDA for Evomela. George Budwell has been writing about healthcare and biotechnology companies at the Motley Fool since 2013. His primary interests are novel small molecule drugs, next generation vaccines, and cell therapies.
Why is Spectrum Pharmaceuticals stock plunging today?
Aug 06, 2021 · Shares of Spectrum Pharmaceuticals ( SPPI -5.82% ) were crashing 26.3% lower as of 11:14 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Food and Drug...
What will Spectrum Pharmaceuticals'share price reach in the next year?
Jul 30, 2020 · Spectrum Pharmaceuticals is offering 21,666,667 shares of its common stock for $3 per share. Also, the company is granting underwriters a 30-day option to purchase an additional 3,250,000 shares.
Should you buy Spectrum Pharmaceuticals (SPR) stock?
Spectrum Pharmaceuticals' stock drops after the company receives a dreaded CRL from the FDA for Evomela. What: Spectrum Pharmaceuticals ( SPPI -5.26% ), …
What is Spectrum Pharmaceuticals (SPPI) stock's ticker?
Dec 21, 2018 · What happened Shares of Spectrum Pharmaceuticals ( SPPI 3.19%), a biopharmaceutical company focused on oncology treatments, are sliding after the Food and Drug Administration refused to designate...
See more
Apr 10, 2022 · Spectrum Pharmaceuticals' stock was trading at $2.39 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, SPPI stock has decreased by 49.8% and is now trading at $1.20. View which stocks have been most impacted by COVID-19.
Will Spectrum Pharmaceuticals stock go up?
Is Spectrum Pharmaceuticals a good stock to buy?
Is Spectrum Pharmaceuticals a good company?
Will Sppi get FDA approval?
Will Rolontis get approved?
Should I invest in SPPI?
Who owns SPPI stock?
| Stockholder | Stake | Shares owned |
|---|---|---|
| BlackRock Fund Advisors | 15.16% | 26,859,820 |
| Armistice Capital LLC | 5.46% | 9,665,756 |
| The Vanguard Group, Inc. | 5.16% | 9,148,197 |
| Millennium Management LLC | 4.30% | 7,619,744 |
What is Rolontis?
Is Spectrum Pharmaceuticals a buy right now?
2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Spectrum Pharmaceuticals in the last twelve months. There are cur...
How has Spectrum Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?
Spectrum Pharmaceuticals' stock was trading at $2.39 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World...
When is Spectrum Pharmaceuticals' next earnings date?
Spectrum Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, March 17th 2022. View our earnings forecast...
How can I listen to Spectrum Pharmaceuticals' earnings call?
Spectrum Pharmaceuticals will be holding an earnings conference call on Thursday, March 17th at 4:30 PM Eastern. Interested parties can register fo...
How were Spectrum Pharmaceuticals' earnings last quarter?
Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) announced its earnings results on Wednesday, November, 10th. The biotechnology company reported ($0.21...
What price target have analysts set for SPPI?
2 brokers have issued 1 year price targets for Spectrum Pharmaceuticals' stock. Their forecasts range from $4.00 to $6.00. On average, they expect...
Who are Spectrum Pharmaceuticals' key executives?
Spectrum Pharmaceuticals' management team includes the following people: Thomas J. Riga , President, Chief Executive Officer & Director ( Linked...
What is Joseph Turgeon's approval rating as Spectrum Pharmaceuticals' CEO?
2 employees have rated Spectrum Pharmaceuticals CEO Joseph Turgeon on Glassdoor.com . Joseph Turgeon has an approval rating of 47% among Spectrum...
Who are some of Spectrum Pharmaceuticals' key competitors?
Some companies that are related to Spectrum Pharmaceuticals include Amgen (AMGN) , Gilead Sciences (GILD) , Regeneron Pharmaceuticals (REGN) ,...
The company announced the pricing of a public offering of common stock
A Fool since 2019, Prosper's writing focuses primarily on the healthcare sector. Passionate about teaching and learning, he enjoys helping others make better decisions about their finances -- and enjoys it just as much when they return the favor. In his free time, you'll find him curling up with a good book or doing math.
What happened
Shares of Spectrum Pharmaceuticals ( NASDAQ:SPPI), a small-cap biopharmaceutical company that focuses on cancer treatments, are down by 20.2% as of 12:18 p.m. EDT on Thursday, after the drugmaker announced the pricing of a public offering of common stock before the market opened today.
So what
Spectrum Pharmaceuticals is offering 21,666,667 shares of its common stock for $3 per share. Also, the company is granting underwriters a 30-day option to purchase an additional 3,250,000 shares. It expects to raise about $65 million in gross proceeds through this public offering of common stock, which should close on Aug. 3.
Now what
On Tuesday, Spectrum Pharmaceuticals' shares soared by more than 20%. The catalyst for these gains was the release of positive data from a clinical trial for one of its pipeline candidates called Poziotinib, which is an experimental treatment for non-small cell lung cancer. Meanwhile, the U.S.
What is Spectrum Pharmaceuticals?
Shares of Spectrum Pharmaceuticals ( NASDAQ:SPPI), a biopharmaceutical company focused on oncology treatments, are sliding after the Food and Drug Administration refused to designate the company's lung cancer candidate a Breakthrough Therapy.
Is spectrum a breakthrough drug?
Earning a breakthrough designation usually isn't hard: You simply need to show signs that your drug can outperform available options. Spectrum reported an impressive 40% response rate among 30 lung cancer patients who had relapsed multiple times, which should be enough for the designation. With this in mind, investors are worried this program is more troublesome than it appears.
When will Spectrum Pharmaceuticals release its earnings?
Spectrum Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021. View our earnings forecast for Spectrum Pharmaceuticals.
What is the ticker symbol for Spectrum Pharmaceuticals?
Spectrum Pharmaceuticals trades on the NASDAQ under the ticker symbol "SPPI."
How much does Spectrum Pharmaceuticals make?
How much money does Spectrum Pharmaceuticals make? Spectrum Pharmaceuticals has a market capitalization of $676.77 million and generates $109.33 million in revenue each year. The biotechnology company earns $-160,870,000.00 in net income (profit) each year or ($1.38) on an earnings per share basis.
Is Spectrum Pharmaceuticals a buy?
Spectrum Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Does Spectrum Pharmaceuticals pay dividends?
Spectrum Pharmaceuticals does not currently pay a dividend.
When did Spectrum Pharmaceuticals receive a response letter?
On August 6, 2021, Spectrum Pharmaceuticals announced receipt of a Complete Response Letter ("CRL") from the FDA regarding the ROLONTIS BLA. The CRL cited deficiencies related to manufacturing and indicated that a reinspection of Spectrum Pharmaceuticals' manufacturing facility will be necessary. On this news, Spectrum Pharmaceuticals' stock price fell more than 21%, damaging investors.
When is Spectrum Pharmaceuticals class action lawsuit?
(NASDAQ: SPPI) securities between December 27, 2018 and August 5, 2021, inclusive (the "Class Period") have until November 1, 2021 to seek appointment as lead plaintiff in the Spectrum Pharmaceuticals class action lawsuit. The Spectrum Pharmaceuticals class action lawsuit charges Spectrum Pharmaceuticals and certain of its top executives with violations of the Securities Exchange Act of 1934. The Spectrum Pharmaceuticals class action lawsuit ( Luo v. Spectrum Pharmaceuticals, Inc., No. 21-cv-01612) was commenced on August 31, 2021 in the District of Nevada and is assigned to Judge Jennifer A. Dorsey.
What is a lead plaintiff in Spectrum Pharmaceuticals?
THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased Spectrum Pharmaceuticals securities during the Class Period to seek appointment as lead plaintiff in the Spectrum Pharmaceuticals class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Spectrum Pharmaceuticals class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Spectrum Pharmaceuticals class action lawsuit. An investor's ability to share in any potential future recovery of the Spectrum Pharmaceuticals class action lawsuit is not dependent upon serving as lead plaintiff.
What is a class action lawsuit against Spectrum Pharmaceuticals?
The Spectrum Pharmaceuticals class action lawsuit alleges that, throughout the Class Period, defendants made false and misleading statements and failed to disclose that: (i) the ROLONTIS manufacturing facility maintained deficient controls and/or procedures; (ii) the foregoing deficiencies decreased the likelihood that the FDA would approve the ROLONTIS BLA in its current form; (iii) Spectrum Pharmaceuticals had therefore materially overstated the ROLONTIS BLA's approval prospects; and (iv) as a result, Spectrum Pharmaceuticals' public statements were materially false and misleading at all relevant times.
Do past results guarantee future outcomes?
Past results do not guarantee future outcomes.
Shares of the household-products maker sold off on a weak earnings report
Fool since 2011. I write about consumer goods, the big picture, and whatever else piques my interest. Follow me on Twitter to see my latest articles, and for commentary on hot topics in retail and the broad market. Follow @tmfbowman
What happened
Shares of Spectrum Brands Holdings Inc. ( NYSE:SPB) were falling today after the parent of household-product brands like Rayovac, Remington, and Iams posted a disappointing fourth-quarter earnings report. As of 11:12 a.m. EST, the stock was down 19.3%.
So what
Organic sales increased 0.4% in the period, and overall revenue was unchanged at $787.8 million, but that missed estimates at $801 million. Its home and garden and global pet supplies segments were particularly weak, seeing revenue fall 6.2% and 2.3%, respectively.
Now what
Investors don't seem to agree with Maura's assessment, and the company's outlook for 2019 did little to assuage their concerns. Management called for meaningful sales growth from continuing operations in 2018 but projected full-year adjusted EBITDA of $560 to $580 million, which was below the analyst consensus at $635.8 million.
